Rank
16
Eagle Pharmaceuticals
Courtesy of Eagle Pharmaceuticals
- Previous Rank
- Revenue 3 Yr Annual Growth Rate109
- Revenue 3 Yr Growth Rank1
- EPS 3 Yr Annual Growth Rate392
- EPS 3 Yr Growth Rank1
- Total Return 3 Yr Annual Rate-2
- Total Return 3 Yr Rank97
In an era of drug development that’s produced seeming miracles like gene editing and cancer immunotherapy, the business of “injectables” may come across as quaint. But there’s nothing boring about coming up with new ways of mixing and administering therapies in a way that helps patients in novel ways. And there’s certainly nothing boring about a 36% return on shareholder investment in 2018 alone. Eagle Pharmaceuticals is a standout among its specialty pharmaceutical peers for investors, no matter how bread-and-butter its aspirations may seem.
Company Information
| Location | Woodcliff Lake, N.J. |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Current Streak | - |
| Years on List | 1 |
| CEO | Scott Tarriff |
| Website | www.eagleus.com |
Revenue, Net Income
| Revenue past four quarters ($M) | $207 |
| Net Income past four quarters ($M) | $32 |
Growth Rates and Ranks
| Revenue 3 Yr Growth Rank | 1 |
| Revenue 3 Yr Annual Growth Rate | 109% |
| EPS 3 Yr Growth Rank | 1 |
| EPS 3 Yr Annual Growth Rate | 392% |
| Total Return 3 Yr Rank | 97 |
| Total Return 3 Yr Annual Rate | -2% |
| Beat S&P 500 (11.9%) | no |
| P/E Ratio | 32 |